restor3d and Conformis entered into a definitive merger agreement in late June 2023 under which restor3d will acquire all outstanding shares of Conformis’ common stock. The transaction is slated to close by the end of the third quarter of 2023 and could breathe fresh life into Conformis’ technology and intellectual property.
Our chart of the month shows Conformis’ product sales as well as revenue from royalties and licensing over the last 10 years. The company’s product sales peaked in 2016 with a total of nearly $79 million. Revenues remained steady over the next several years, but the pandemic hit Conformis especially hard. The company’s annual revenue declined -24% from 2019 to 2020 and continued to slide in the years since.
A partnership with Stryker for patient-specific instruments never brought the return Conformis hoped for, and the company’s Platinum Services business model failed to gain traction. However, the company’s IP remains valuable. restor3D could unlock the technology’s full potential through its strength in artificial intelligence, digital automation and 3D printing.
As healthcare costs are driven down, and procedures shift to outpatient settings, the combined company could create a very compelling offering that spans a large cross-section of orthopedics.
restor3d and Conformis entered into a definitive merger agreement in late June 2023 under which restor3d will acquire all outstanding shares of Conformis’ common stock. The transaction is slated to close by the end of the third quarter of 2023 and could breathe fresh life into Conformis’ technology and intellectual property.
Our chart of...
restor3d and Conformis entered into a definitive merger agreement in late June 2023 under which restor3d will acquire all outstanding shares of Conformis’ common stock. The transaction is slated to close by the end of the third quarter of 2023 and could breathe fresh life into Conformis’ technology and intellectual property.
Our chart of the month shows Conformis’ product sales as well as revenue from royalties and licensing over the last 10 years. The company’s product sales peaked in 2016 with a total of nearly $79 million. Revenues remained steady over the next several years, but the pandemic hit Conformis especially hard. The company’s annual revenue declined -24% from 2019 to 2020 and continued to slide in the years since.
A partnership with Stryker for patient-specific instruments never brought the return Conformis hoped for, and the company’s Platinum Services business model failed to gain traction. However, the company’s IP remains valuable. restor3D could unlock the technology’s full potential through its strength in artificial intelligence, digital automation and 3D printing.
As healthcare costs are driven down, and procedures shift to outpatient settings, the combined company could create a very compelling offering that spans a large cross-section of orthopedics.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
